Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Urinary Bladder Neoplasms 9 Non-Muscle Invasive Bladder Neoplasms 3 Ureteral Neoplasms 1 Neoplasms 1 Muscle Invasive Bladder Urothelial Carcinoma 1 Carcinoma in Situ 1

Interventions

Specimen Handling 6 pembrolizumab 4 enfortumab vedotin 4 Magnetic Resonance Spectroscopy 4 Gemcitabine 3 cabozantinib 2 Nivolumab 2 Carboplatin 2 Biopsy 2 relatlimab 1 eribulin 1 erdafitinib 1 avelumab 1 atezolizumab 1 Watchful Waiting 1 Standard of Care 1 Practice Guidelines as Topic 1 Plasmapheresis 1 Plasma Exchange 1 Observation 1 Lenalidomide 1 Ipilimumab 1 Doxorubicin 1 Cystoscopy 1 Contrast Media 1 Cisplatin 1 Central Venous Catheters 1 CTLA-4 Antigen 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ureteral Neoplasms × Cystoscopy × 90 days × Clear all

NCT03244384 2026-05-29

AMBASSADOR

National Cancer Institute (NCI)

Phase 3 Active not recruiting

Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡